The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States
article has not abstract
Vyšlo v časopise:
The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States. PLoS Med 5(1): e1. doi:10.1371/journal.pmed.0050001
Kategorie:
Policy Forum
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.0050001
Souhrn
article has not abstract
Zdroje
1. KefauverE
1965
In a few hands
Harmondsworth
Penguin
2. FroudJJohalSLeaverAWilliamsK
2006
Financialization and strategy: narrative and numbers
London and New York
Routledge
3. General Accounting Office
2002
Prescription drugs: FDA oversight of direct-to-consumer advertising has limitations.
Available: http://www.gao.gov/new.items/d03177.pdf. Accessed 27 November 2007
4. IMS Health
2005
Total U.S. promotional spend by type, 2004.
Accessed 4 November 2006 at http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_49695992_75406357,00.html
5. Pharmaceutical Research and Manufacturers of America
2006
Pharmaceutical industry profile 2006.
Available: http://www.phrma.org/files/2006%20Industry%20Profile.pdf. Accessed 27 November 2007
6. HensleySMartinezB
2005 July 15
To sell their drugs, companies increasingly rely on doctors.
Wall Street Journal
A1
7. Quintiles Transnational
2001
Promoting drugs through physician meetings and events: Pfizer leads the way; antidepressants are top category.
Accessed 3 March 2002 at http://www.quintiles.com/products_and_services/informatics/scott_levin/press_releases/press_release/1,1254,209,00.html
8. La PumaJSeltzerJ
2002
Phase IV market steams ahead.
CenterWatch
9
1, 9-13
9. LauzonL-PHasbaniM
2006
Analyse socio-économique: industrie pharmaceutique mondiale pour la période de dix ans 1996–2005
Montreal
Chaire d'études socio-économiques de l'UQAM
10. CAM Group
2005
Total U.S. promotional activity for 2004. CAM USA Newsletter.
Accessed 22 July 2007 at http://csd.cam-group.com/www_assets/pages/downloads/USNewsletterQ404.pdf
11. IMS Health
2006
Channel distribution by U.S. sales.
Available: http://www.imshealth.com/ims/portal/front/articleC/0,2777,6652_80408863_80411875,00.htm. Accessed 28 November 2007
12. IMS Health
2006
Global pharmaceutical sales, 1999–2006.
Available: http://www.imshealth.com/ims/portal/front/articleC/0,2777,6652_80528184_80528202,00.html. Accessed 27 November 2007
13. CAM Group
2005
4th quarter 2004 promotional activity. CAM Group News.
Accessed 22 July 2007 at http://csd.cam-group.com/www_assets/pages/downloads/CAMNewsletterQ404.pdf
14. IMS Health
2004
Total U.S. value of free product samples, 2004.
Accessed 4 November 2006 at http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_78152267_78152297,00.html
15. National Science Foundation
2006
U.S. industrial R&D performers report increased expenditures for 2004.
Available: http://www.nsf.gov/statistics/infbrief/nsf07304/#notes. Accessed 27 November 2007
16. GøtzschePCHróbjartssonAJohansenHKHaahrMTAltmanDG
2007
Ghost authorship in industry-initiated randomised trials.
PLoS Med
4
e19
doi:10.1371/journal.pmed.0040019
17. SteinmanMABeroLAChrenMMLandefeldCS
2006
Narrative review: the promotion of gabapentin: an analysis of internal industry documents.
Ann Intern Med
145
284
293
18. GencarelliDM
2005
One pill, many prices: variation in prescription drug prices in selected government programs. National Health Policy Forum.
Available: http://www.nhpf.org/pdfs_ib/IB807_DrugPricing_08-29-05.pdf. Accessed 27 November 2007
19. Pharmaceutical Research and Manufacturers of America
2005
America's pharmaceutical companies increase Katrina donations; more than $100 million in medicines, cash donated so far.
Available: http://www.liberty-page.com/issues/comparison/pharm.html. Accessed 27 November 2007
20. Organization for Economic Cooperation and Development
2006
OECD health data 2006. Organization for Economic Cooperation and Development.
21. IMS Health
2004
U.S. purchase activity by channel, 2004.
Accessed 4 November 2006 at http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_49695983_69891354,00.html
22. AngellM
2004
The truth about the drug companies: how they deceive us and what to do about it
New York
Random House
23. Office of Technology Assessment
1993
Pharmaceutical R&D: costs, risks and rewards
Washington (D. C.)
US Government Printing Office
24. JacobzoneS
2000
Pharmaceutical policies in OECD countries: reconciling social and industrial goals
Paris
OECD Publishing
Available: http://ideas.repec.org/p/oec/elsaaa/40-en.html. Accessed 28 November 2007
25. Consumers International
2006
Branding the cure: a consumer perspective on corporate social responsibility, drug promotion and the pharmaceutical industry in Europe
London
Consumers International
26. Centers for Medicare and Medicaid Services
2003
Health care industry market update: pharmaceuticals.
Available: http://www.fdcpa.com/CMS%20Pharmaceuticals%20Jan%202003.pdf. Accessed 28 November 2007
27. Families USA
2002
Profiting from pain: where prescription drug dollars go.
Available: http://www.familiesusa.org/assets/pdfs/PPreport89a5.pdf. Accessed 28 November 2007.2.254
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2008 Číslo 1
- Pleiotropní účinky statinů na kardiovaskulární systém
- Role praktického lékaře v péči o pacienta s familiární hypercholesterolémií
- Hydroresponzivní krytí v epitelizační fázi hojení rány
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
Najčítanejšie v tomto čísle
- Model-Based Insights into Multi-Host Transmission and Control of Schistosomiasis
- New Insights into Impaired Muscle Glycogen Synthesis
- Targeting PDGF Signaling in Carcinoma-Associated Fibroblasts Controls Cervical Cancer in Mouse Model
- The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States